All IndicationsPhase 3Phase 2Phase 2Phase 2Phase 2
🛡️
6
Companies
6
Drug Programs
1
Phase 3
0
Upcoming PDUFAs
Competitors
PHM.MC
PharmaMar, S.A.
Levalbuterol
ALPMY
Astellas Pharma
Tacrolimus Inhalation Aerosol
LLY
Eli Lilly and Company
Brenipatide
JNJ
Johnson & Johnson
JNJ39758979
RHHBY
Roche Holding AG
Dual Integrin Antagonist
TEVA
Teva Pharmaceuticals
asthma inhalers
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| PHM.MC PharmaMar, S.A. | Levalbuterol | Phase 3 | — | — | — |
| ALPMY Astellas Pharma | Tacrolimus Inhalation Aerosol | Phase 2 | — | — | — |
| LLY Eli Lilly and Company | Brenipatide | Phase 2 | — | — | — |
| JNJ Johnson & Johnson | JNJ39758979 | Phase 2 | — | — | — |
| RHHBY Roche Holding AG | Dual Integrin Antagonist | Phase 2 | — | — | — |
| TEVA Teva Pharmaceuticals | asthma inhalers | — | — | — | — |
Development Stage Distribution
Unknown
1
Phase 3
1
Phase 2
4
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.